Tevogen Inc. Warrant (TVGNW)

About TVGNW

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune s…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

18

Fundamentals

1-day range

$0.0665$0.0686

Market cap

$320.8K

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

—

Dividend yield

—

Beta

-0.07

Avg. volume

—

Tevogen Inc. Warrant Competitors

Chosen by industry and closest market cap.

• TVGNW

  Tevogen Inc. Warrant

  $0.0689

  ▼ 1.57%
  Market cap $320.8KP/E —
  $0.0253$0.08
• SLXNW

  Silexion Therapeutics Corp Warrant

  $0.0054

  ▼ 10.00%
  Market cap $21.3KP/E —
  $0.0051$0.1508
• BKHA

  Black Hawk Acquisition Corporation Class A Ordinary Shares

  $6.01

  ▼ 12.26%
  Market cap $—P/E 136.64
  $9.5$23
• BTTC

  Black Titan Corporation Ordinary Shares

  $0.368

  ▼ 6.84%
  Market cap $1.02MP/E —
  $0.3415$10.05
• SCNI

  Scinai Immunotherapeutics Ltd. American Depositary Shares

  $0.752

  ▼ 16.63%
  Market cap $1.30MP/E 0.16
  $0.75$15.65
• SLXN

  Silexion Therapeutics Corp Ordinary Shares

  $0.153

  ▼ 19.05%
  Market cap $1.90MP/E —
  $0.2362$42.6
• CLDI

  Calidi Biotherapeutics Inc. Common Stock

  $0.837

  ▼ 3.79%
  Market cap $4.38MP/E —
  $0.82$27.84

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

9.25M

Total value held

$6.92M

Institutional holders

34